EGFR Mutant-selective Inhibitor QLH11811

Preferred Label : EGFR Mutant-selective Inhibitor QLH11811;

NCIt synonyms : EGFR Inhibitor QLH11811;

NCIt definition : An orally bioavailable, mutant-selective, fourth-generation epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor QLH11811 targets, binds to and inhibits the activity of EGFR with selective mutations, including ex19del, L858R, T790M and C797S, thereby preventing EGFR mutant-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR mutant-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;

Molecule name : QLH-11811; QLH 11811;

NCI Metathesaurus CUI : CL1905410;

Details

Origin ID

C192005;

UMLS CUI

C5784825;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- EGFR Exon 19 Deletion Mutation [NCIt concept]
- EGFR NP_005219.2:p.C797S [NCIt concept]
- EGFR NP_005219.2:p.L858R [NCIt concept]
- EGFR NP_005219.2:p.T790M [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients